Dyspepsia Drug Market Size, Share Trends and Forecast Report 2023-2030

Dyspepsia Drug Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Dyspepsia Drugs Market is Segmented&nbsp;By Disease Type (Functional Dyspepsia, Organic Dyspepsia), By Drug Type (Proton Pump Inhibitors, H-2-receptor Antagonists, Antacids,&nbsp;Antibiotics,&nbsp;Prokinetics,&nbsp;Antidepressants), By&nbsp;Route of Administration (Oral,&nbsp;Parenteral), By Mode (Over the Counter,&nbsp;Prescription,&nbsp;Specialized Clinics), By Distribution Channel (Hospital Pharmacies,&nbsp;Retail Pharmacies,&nbsp;Online Pharmacies),&nbsp; By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030.</h2>

&nbsp;

<h3>Market Overview</h3>

<blockquote>
Global Dyspepsia Drugs Market reached US$ YY million in 2022 and is expected to reach US$ YY&nbsp; million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
</blockquote>

Dyspepsia also referred as indigestion that casues discomfort or pain in the upper abdomen, often after eating or drinking. It is not a disease but symptom of gastroesophageal reflux disease (GERD) and other conditions.

Dyspepsia is a combination of symptoms caused by a variety of underlying reasons such as excessive stomach acid production, gastritis, peptic ulcers, gastroesophageal reflux disease (GERD), and lifestyle factors such as dietary intake and stress.

The aging global population, as well as changing food and lifestyle trends, all contribute to an increase in dyspeptic symptoms, propelling market growth. Technological advances in drug research, particularly in the Proton Pump Inhibitor (PPI) category, have resulted in novel and very effective dyspepsia treatments. Furthermore, the shift toward over-the-counter (OTC) dyspepsia medications provides consumers with easy and readily available solutions.&nbsp;

<h3>Market Scope</h3>

<table cellspacing="0" style="border-collapse:collapse">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			YY%
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Size Available for Years
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2021-2030
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2023-2030
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Data Availability
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$ Mn)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Disease Type, Drug Type, Route of Administration, Mode, Distribution Channel
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America, and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter&rsquo;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

For more details on this report <a href="https://www.datamintelligence.com/download-sample/dyspepsia-market" target="_blank">Request for Sample</a>

&nbsp;

<h3>Market Dynamics: Drivers and Restraints</h3>

The increasing preference for OTC drugs for dyspepsia treatment

Over-the-counter (OTC) dyspepsia drugs are non-prescription medications that are readily available in retail outlets such as pharmacies and are designed to alleviate symptoms of dyspepsia such as abdominal discomfort and bloating. The growing popularity of over-the-counter dyspepsia medications has pushed pharmaceutical companies.

Proton pump inhibitors are the mostly used drugs to treat dyspepsia. For instance, according to the Drug Watch 2023 article, proton pump inhibitors (PPIs) are among the most commonly used drugs in the world. Almost 15 million people in the U.S. use PPIs every year.

Furthermore, many pharmaceutical companies are launching the OTC drugs for dyspepsia. For instance, in January 2022, Glenmark USA acquired ANDAS for four OTC drugs such as famotidine, cetirizine, hydrochloride, lansoprazole from Wockhardt. These OTC drugs are specifically used to treat indigestion, heartburn, anti-allergy, and acid reflux.

Furthermore, the increasing prevalence of dyspepsia, aging population, growing awareness of gastrointestinal health and changing lifestyles and dietary habits are some of the other major factors that are expected to drive the global dyspepsia drugs market over the forecast period.

<h3>Market Dynamics: Restraint</h3>

The side effects associated with dyspepsia drugs is one major factor to restrain the market. Some of the dyspepsia drugs, especially those that reduce stomach acid production, may cause headaches, diarrhea and nausea.

Furthermore, the availability of alternative treatment options can affect the market growth. Those individuals with dyspepsia may prefer alternative treatment such as herbal medicines, dietary modifications, or lifestyle changes over pharmaceutical treatments. These alternative approaches have the potential to draw&nbsp;patients away from standard pharmacological treatments, thereby affecting the market&#39;s growth potential over the forecast period.

<h3>Market Segment Analysis</h3>

The global dyspepsia drugs is segmented based on disease type, drug type, route of administration, mode, distribution channel and region.

The proton pump inhibitor segment accounted for approximately 38.2 % of the market share&nbsp;

The proton pump inhibitors (PPIs) from the product type segment accounted for 38.2% and it is expected to be dominated during the forecast period. The proton pump inhibitors (PPIs) are considered as first line treatment for for functional dyspepsia. PPIs are among the strongest drugs available for gastric suppression that improves functional dyspepsia.

Furthermore, according to NHS Greater Glasgow and Clyde 2022 article, PPIs stands second in most commonly prescribed drug class with almost 1.5 million prescriptions issued yearly by primary care alone. Among these drug class, omeprazole and lansoprazole are higly preferred choice for adults. Also, its availability at OTC makes this drug class a preferred choice for individuals suffering from dyspepsia.

The cost-effectiveness and broad availability of medications like omeprazole, a typical proton pump inhibitor (PPI), increase their popularity among both patients and healthcare practitioners. Omeprazole&#39;s modest cost, around $100.37 for 100 capsules, enables accessibility for a wide range of people, particularly those without complete health insurance coverage. Thus, owing to the above factors the segment is expected to dominate over the forecast period.

<h3>Geographical Analysis</h3>

North America accounted for approximately 37.4% of the market share in 2022

North America is estimated to hold about 37.4% of the total market share throughout the forecast period, owing to the increasing product approvals, rising geriatric population, collaboration with the key players, and others that will drive this region further during the forecast period.

For instance, in March 2023, Marksans Pharma Ltd obtained final approval from the U.S. Food and Drug Administration for its generic version of Famotidine tablets, which are used to treat acid indigestion and heartburn. The US Food and Drug Administration (USFDA) has approved an abbreviated new drug application (ANDA) for Famotidine tablets in strengths of 10 mg and 20 mg for over-the-counter (OTC) usage.

Furthermore, the increasing geriatric population in U.S. is major factor in driving the market forwards. Dyspepsia is more common in elderly people, as it decreases in the production of digestive juices (such as bile, saliva, gastric juice, and enzymes). For instance, according to United States Census Bureau 2023 report, in U.S. older population aging 65 and above has reached about 55.8 million or 16.8%, as it has grown nearly five times faster than the total population over 100 years. Thus, as the age increases the probability of having dyspepsia grows, thereby driving the region market forward over the forecast period.

<h3>COVID-19 Impact Analysis</h3>

Covid 19 had a substantial impact on the global dyspepsia drugs market, as it is a stress-sensitive gut-brain condition, and the COVID-19 epidemic has caused significant anxiety and stress. A population-based survey was conducted to assess the influence of the COVID-19 pandemic on the gastrointestinal and psychological symptoms of FD. According to the survey, the COVID-19 pandemic had a negative impact on FD/IBS individuals, with respondents indicating FD-IBS overlap syndrome as the most important independent factor linked with worsening gastrointestinal symptoms.

Moreover, a clinical trial is&nbsp;ongoing to look into the effect of COVID-19 infection on the symptoms of functional dyspepsia (FD). The study&#39;s goal is to see if COVID-19 infection causes FD or worsens the symptoms of pre-existing FD. The trial is&nbsp;prospective observational research in which patients with FD and COVID-19 infection will be included. The researchers will evaluate the severity of FD symptoms before and after COVID-19 infection in a control group of FD patients who did not develop COVID-19.

<h3>Competitive Landscape</h3>

The major global players in the dyspepsia drugs market include Takeda Pharmaceutical Company Limited, Sanofi, Haleon plc., Procter &amp; Gamble, Abbott, Pfizer Inc., Woodward Pharma Services LLC, Lannett Company, Inc., ANI Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc and among others.

<h3>Key Developments</h3>

<ul>
	<li>In January 2023, metaMe Health, Inc., a prescription digital therapeutics (PDT) company, agreed to licensed gut-directed hypnotherapy protocol for functional dyspepsia, a chronic disorder of the upper gastrointestinal tract that currently lacks substantially effective therapy options.</li>
	<li>In July 2022, Meiji Seika Pharma and Zeria Pharmaceutical granted regulatory approval in Thailand for Acofide (acotiamide) to treat functional dyspepsia.</li>
</ul>

Why Purchase the Report?

<ul>
	<li>To visualize the global dyspepsia drugs market segmentation-based on disease type, drug type, route of administration, mode, distribution channel, and region, as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analyzing trends and co-development</li>
	<li>Excel data sheet with numerous data points of dyspepsia drugs market-level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping available as Excel consisting of key products of all the major players.</li>
</ul>

The global dyspepsia drugs market report would provide approximately 77 tables, 77 figures, and 185 Pages.

<h3>Target Audience 2023</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Disease Type</li>
		<li>Snippet by Drug Type</li>
		<li>Snippet by Route of Administration</li>
		<li>Snippet by Mode</li>
		<li>Snippet by Distribution Channel</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Driver
			<ol>
				<li>The increasing preference for OTC drugs for dyspepsia treatment</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>Side effects associated with the dyspepsia drugs</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Force Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Russia-Ukraine War Impact Analysis</li>
		<li>DMI Opinion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID</li>
			<li>Scenario During COVID</li>
			<li>Scenario Post COVID</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Disease Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Attractiveness Index, By Disease Type</li>
		</ol>
		</li>
		<li>Functional Dyspepsia*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Organic Dyspepsia</h3>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Drug Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type&nbsp;</li>
			<li>Market Attractiveness Index, By Drug Type&nbsp;</li>
		</ol>
		</li>
		<li>Proton Pump Inhibitors*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)
			<ol>
				<li>Lansoprazole</li>
				<li>Omeprazole</li>
				<li>Esomeprazole</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>H-2-receptor Antagonists
		<ol>
			<li>Cimetidine</li>
			<li>Famotidine</li>
			<li>Nizatidine</li>
		</ol>
		</li>
		<li>Antacids
		<ol>
			<li>Calcium Carbonate</li>
			<li>Loperamide&nbsp;</li>
			<li>Simethicone</li>
			<li>Sodium Bicarbonate</li>
		</ol>
		</li>
		<li>Antibiotics
		<ol>
			<li>Amoxicillin&nbsp;</li>
			<li>Clarithromycin</li>
			<li>Metronidazole&nbsp;</li>
			<li>Tetracycline</li>
		</ol>
		</li>
		<li>Prokinetics
		<ol>
			<li>Bethanechol&nbsp;</li>
			<li>Metoclopramide</li>
		</ol>
		</li>
		<li>Antidepressants</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Route of Administration</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Attractiveness Index, By Route of Administration</li>
		</ol>
		</li>
		<li>Oral*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Parenteral&nbsp;</h3>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Mode</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode</li>
			<li>Market Attractiveness Index, By Mode</li>
		</ol>
		</li>
		<li>Over the Counter*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Prescription</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Distribution Channel</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Hospital Pharmacies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Retail Pharmacies</li>
		<li>Online Pharmacies</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode</li>
			<li>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode</li>
			<li>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode</li>
			<li>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode</li>
			<li>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>Takeda Pharmaceutical Company Limited.&nbsp;
		<ol>
			<li>Company Overview</li>
			<li>Product Type Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Sanofi</li>
		<li>Haleon plc.</li>
		<li>Procter &amp; Gamble</li>
		<li>Abbott</li>
		<li>Pfizer Inc.</li>
		<li>Woodward Pharma Services LLC</li>
		<li>Lannett Company, Inc.</li>
		<li>ANI Pharmaceuticals, Inc.&nbsp;</li>
		<li>Salix Pharmaceuticals, Inc&nbsp;(*LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global Dyspepsia Drug Market Value, By Disease Type, 2022, 2026 &amp; 2030 (US$ Million)

Table 2 Global Dyspepsia Drug Market Value, By Drug Type, 2022, 2026 &amp; 2030 (US$ Million)

Table 3 Global Dyspepsia Drug Market Value, By Route of Administration, 2022, 2026 &amp; 2030 (US$ Million)

Table 4 Global Dyspepsia Drug Market Value, By Mode, 2022, 2026 &amp; 2030 (US$ Million)

Table 5 Global Dyspepsia Drug Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 (US$ Million)

Table 6 Global Dyspepsia Drug Market Value, By Region, 2022, 2026 &amp; 2030 (US$ Million)

Table 7 Global Dyspepsia Drug Market Value, By Disease Type, 2022, 2026 &amp; 2030 (US$ Million)

Table 8 Global Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 9 Global Dyspepsia Drug Market Value, By Drug Type, 2022, 2026 &amp; 2030 (US$ Million)

Table 10 Global Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 11 Global Dyspepsia Drug Market Value, By Route of Administration, 2022, 2026 &amp; 2030 (US$ Million)

Table 12 Global Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 13 Global Dyspepsia Drug Market Value, By Mode, 2022, 2026 &amp; 2030 (US$ Million)

Table 14 Global Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 15 Global Dyspepsia Drug Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 (US$ Million)

Table 16 Global Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 17 Global Dyspepsia Drug Market Value, By Region, 2022, 2026 &amp; 2030 (US$ Million)

Table 18 Global Dyspepsia Drug Market Value, By Region, 2021-2030 (US$ Million)

Table 19 North America Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 20 North America Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 21 North America Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 22 North America Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 23 North America Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 North America Dyspepsia Drug Market Value, By Country, 2021-2030 (US$ Million)

Table 25 South America Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 26 South America Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 27 South America Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 28 South America Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 29 South America Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 South America Dyspepsia Drug Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Europe Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 32 Europe Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 33 Europe Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 34 Europe Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 35 Europe Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 36 Europe Dyspepsia Drug Market Value, By Country, 2021-2030 (US$ Million)

Table 37 Asia-Pacific Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 38 Asia-Pacific Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 39 Asia-Pacific Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 40 Asia-Pacific Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 41 Asia-Pacific Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 42 Asia-Pacific Dyspepsia Drug Market Value, By Country, 2021-2030 (US$ Million)

Table 43 Middle East &amp; Africa Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 44 Middle East &amp; Africa Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 45 Middle East &amp; Africa Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 46 Middle East &amp; Africa Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 47 Middle East &amp; Africa Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 48 Takeda Pharmaceutical Company Limited.: Overview

Table 49 Takeda Pharmaceutical Company Limited.: Product Portfolio

Table 50 Takeda Pharmaceutical Company Limited.: Key Developments

Table 51 Sanofi: Overview

Table 52 Sanofi: Product Portfolio

Table 53 Sanofi: Key Developments

Table 54 Haleon plc.: Overview

Table 55 Haleon plc.: Product Portfolio

Table 56 Haleon plc.: Key Developments

Table 57 Procter &amp; Gamble: Overview

Table 58 Procter &amp; Gamble: Product Portfolio

Table 59 Procter &amp; Gamble: Key Developments

Table 60 Abbott: Overview

Table 61 Abbott: Product Portfolio

Table 62 Abbott: Key Developments

Table 63 Pfizer Inc.: Overview

Table 64 Pfizer Inc.: Product Portfolio

Table 65 Pfizer Inc.: Key Developments

Table 66 Woodward Pharma Services LLC: Overview

Table 67 Woodward Pharma Services LLC: Product Portfolio

Table 68 Woodward Pharma Services LLC: Key Developments

Table 69 Lannett Company, Inc.: Overview

Table 70 Lannett Company, Inc.: Product Portfolio

Table 71 Lannett Company, Inc.: Key Developments

Table 72 ANI Pharmaceuticals, Inc.: Overview

Table 73 ANI Pharmaceuticals, Inc.: Product Portfolio

Table 74 ANI Pharmaceuticals, Inc.: Key Developments

Table 75 Salix Pharmaceuticals, Inc.: Overview

Table 76 Salix Pharmaceuticals, Inc.: Product Portfolio

Table 77 Salix Pharmaceuticals, Inc.: Key Developments

List of Figures

Figure 1 Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 2 Global Dyspepsia Drug Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure 3 Global Dyspepsia Drug Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 4 Global Dyspepsia Drug Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 5 Global Dyspepsia Drug Market Share, By Mode, 2022 &amp; 2030 (%)

Figure 6 Global Dyspepsia Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 7 Global Dyspepsia Drug Market Share, By Region, 2022 &amp; 2030 (%)

Figure 8 Global Dyspepsia Drug Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 9 Functional Dyspepsia Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 10 Organic Dyspepsia Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 11 Global Dyspepsia Drug Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 12 Proton Pump Inhibitors Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 13 H-2-receptor Antagonists Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 14 Antacids Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 15 Antibiotics Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 16 Prokinetics Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 17 Antidepressants Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 18 Global Dyspepsia Drug Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 19 Oral Route of Administration in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 20 Parenteral Route of Administration in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 21 Global Dyspepsia Drug Market Y-o-Y Growth, By Mode, 2022-2030 (%)

Figure 22 Over the Counter Mode in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 23 Prescription Mode in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 24 Global Dyspepsia Drug Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 25 Hospital Pharmacies Distribution Channel in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 26 Retail Pharmacies Distribution Channel in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 27 Online Pharmacies Distribution Channel in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 28 Global Dyspepsia Drug Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 29 North America Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 30 Asia-Pacific Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 31 Europe Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 32 South America Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 33 Middle East and Africa Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 34 North America Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 35 North America Dyspepsia Drug Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure 36 North America Dyspepsia Drug Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 37 North America Dyspepsia Drug Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 38 North America Dyspepsia Drug Market Share, By Mode, 2022 &amp; 2030 (%)

Figure 39 North America Dyspepsia Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 40 North America Dyspepsia Drug Market Share, By Country, 2022 &amp; 2030 (%)

Figure 41 South America Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 42 South America Dyspepsia Drug Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure 43 South America Dyspepsia Drug Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 44 South America Dyspepsia Drug Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 45 South America Dyspepsia Drug Market Share, By Mode, 2022 &amp; 2030 (%)

Figure 46 South America Dyspepsia Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 47 South America Dyspepsia Drug Market Share, By Country, 2022 &amp; 2030 (%)

Figure 48 Europe Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 49 Europe Dyspepsia Drug Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure 50 Europe Dyspepsia Drug Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 51 Europe Dyspepsia Drug Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 52 Europe Dyspepsia Drug Market Share, By Mode, 2022 &amp; 2030 (%)

Figure 53 Europe Dyspepsia Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 54 Europe Dyspepsia Drug Market Share, By Country, 2022 &amp; 2030 (%)

Figure 55 Asia-Pacific Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 56 Asia-Pacific Dyspepsia Drug Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure 57 Asia-Pacific Dyspepsia Drug Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 58 Asia-Pacific Dyspepsia Drug Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 59 Asia-Pacific Dyspepsia Drug Market Share, By Mode, 2022 &amp; 2030 (%)

Figure 60 Asia-Pacific Dyspepsia Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 61 Asia-Pacific Dyspepsia Drug Market Share, By Country, 2022 &amp; 2030 (%)

Figure 62 Middle East &amp; Africa Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 63 Middle East &amp; Africa Dyspepsia Drug Market Share, By Disease Type, 2022 &amp; 2030 (%)

Figure 64 Middle East &amp; Africa Dyspepsia Drug Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 65 Middle East &amp; Africa Dyspepsia Drug Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 66 Middle East &amp; Africa Dyspepsia Drug Market Share, By Mode, 2022 &amp; 2030 (%)

Figure 67 Middle East &amp; Africa Dyspepsia Drug Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 68 Takeda Pharmaceutical Company Limited.: Financials

Figure 69 Sanofi: Financials

Figure 70 Haleon plc.: Financials

Figure 71 Procter &amp; Gamble: Financials

Figure 72 Abbott: Financials

Figure 73 Pfizer Inc.: Financials

Figure 74 Woodward Pharma Services LLC: Financials

Figure 75 Lannett Company, Inc.: Financials

Figure 76 ANI Pharmaceuticals, Inc.: Financials

Figure 77 Salix Pharmaceuticals, Inc.: Financials

<h3>&nbsp;</h3>

Dyspepsia Drug Market Size, Share, Industry, Forecast and outlook (2023-2030)

Gastrointestinal Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 October 27

Starting from

Esomeprazole Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2022 July 06

Starting from

Crohn’s Disease Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 October 10

Starting from

Proton Pump Inhibitors Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 October 03

Starting from

Gastroparesis Drugs Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 September 27

Starting from

Achalasia Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 September 21

Starting from